Technology

Artificial Intelligence Big Data Cloud Computing Cyber Security Data Management Electronics Enterprise & Network Technology Financial Technology Hardware Mobile & Wireless Nanotechnology Semiconductor Software Telecommunications
News Release Digital Asset Direct

USDT on TRON Surpasses $80 Billion, Strengthening TRON’s Position as the Leading Stablecoin Network

TRON DAO

June 26, 2025 - Geneva, Switzerland - TRON DAO announced today that the total circulating supply of USDT on the TRON blockchain has exceeded $80 billion, further cementing TRON’s position as the top blockchain for USDT activity. With USDT holding more than 63 percent of the global stablecoin market and surpassing 155 billion dollars in circulation, over half of that supply is issued on TRON. Since January 2025, the supply of USDT issued on the TRON network has grown by approximately 20 billion, according to a data platform Token Terminal. TRON continues to lead all blockchain networks in USDT issuance, transaction volume, and daily user activity. TRON has established itself as the preferred settlement network for stablecoins, hosting around 60 percent of payment transaction volume. Its scale and efficiency continue to position it as the backbone for digital dollar movement across borders and diverse financial applications. As of June 2025, TRON processes over 8.9 million daily transactions and has surpassed 315 million total user accounts. Additionally, the network facilitates an average of $21.5 billion in daily USDT transfers. With over 1 million unique wallets transacting USDT each day, TRON also leads in active stablecoin wallet usage, representing 28 percent of global active addresses. With stablecoins playing an increasingly important role in cross-border settlement, financial access, and dollarization in emerging markets, TRON has established itself as one of the most widely used blockchain networks in the world. Its combination of scale, speed, and low transaction costs has made it the preferred environment for stablecoin activity worldwide. “TRON’s success is grounded in its alignment with the core values of crypto—openness, user empowerment, and real-world utility,” said Justin Sun, founder of TRON. “USDT on TRON has become the go-to choice for millions of people because it works—it’s fast, efficient, and easy to use. The TRON ecosystem remains focused on building reliable infrastructure for the next generation of digital finance.” TRON’s leadership in the stablecoin space continues to evolve to meet growing institutional demand. In April 2025, World Liberty Financial chose TRON to launch its USD1 stablecoin, which began minting earlier this month. Additionally, the TRON ecosystem has deepened its focus on financial compliance through the T3 Financial Crime Unit (T3 FCU), a joint initiative with Tether and TRM Labs. Since launch, T3 FCU has worked with law enforcement agencies worldwide to freeze over $160 million linked to illicit activity. As the digital dollar economy continues to expand, TRON remains a core pillar of the infrastructure driving greater efficiency and financial inclusion. About TRON DAO TRON DAO is a community-governed DAO dedicated to accelerating the decentralization of the internet via blockchain technology and dApps. Founded in September 2017 by H.E. Justin Sun, the TRON blockchain has experienced significant growth since its MainNet launch in May 2018. TRON hosts the largest circulating supply of USD Tether (USDT) stablecoin, exceeding $80 billion. As of June 2025, the TRON blockchain has recorded over 315 million in total user accounts, more than 10 billion in total transactions, and over $21 billion in total value locked (TVL), based on TRONSCAN. TRONNetwork | TRONDAO | X | YouTube | Telegram | Discord | Reddit | GitHub | Medium | Forum Media Contact Yeweon Park press@tron.network Contact Details Yeweon Park press@tron.network Company Website https://trondao.org/

June 26, 2025 12:46 PM Eastern Daylight Time

Image

News Release

Rankulate Launches to Help Businesses Scale SEO With Lean ROI-Focused Strategies

Rev Up Marketers

Rankulate, a newly launched SEO consultancy, officially opens its doors to help businesses scale organic growth through lean, results-driven strategies. Founded by SEO expert Adrian Podyma, Rankulate offers consultant-led support tailored for startups, scale-ups, and enterprise teams seeking clarity, speed, and measurable performance without the overhead of a traditional agency. What sets Rankulate apart is its commitment to hands-on leadership and high-impact execution. Every strategy is directly overseen by Podyma, ensuring senior-level insight, tight alignment with business goals, and faster implementation. The consultancy adapts to the scale of each project, assembling the right specialists as needed—without losing strategic focus or adding layers of complexity. With over a decade of experience leading SEO programs across diverse industries—and managing teams of up to 20 SEO professionals per project—Podyma brings both strategic clarity and operational depth to each engagement. Rankulate is positioned to support businesses navigating complex SEO challenges with a streamlined, performance-first approach. “SEO should be a growth engine, not a bottleneck,” says founder Adrian Podyma. “Rankulate was built to deliver lean, accountable, ROI-focused SEO—led by someone who’s been in the trenches.” Rankulate is now accepting clients across B2B, SaaS, and e-commerce sectors. To learn more, visit [ www.rankulate.com ]. About Rankulate Rankulate is a boutique SEO consultancy based in Katowice, Poland, founded by Adrian Podyma. Focused on lean, ROI-driven strategies, the firm helps businesses solve complex SEO challenges through personalised, consultant-led support. With deep expertise across technical SEO, content strategy, and scalable execution, Rankulate delivers clarity, speed, and measurable growth—without the unnecessary layers of traditional agencies. Learn more at [ www.rankulate.com ]. Contact Details Rankulate Adrian Podyma contact@rankulate.com Company Website https://rankulate.com/

June 26, 2025 11:19 AM Eastern Daylight Time

Bonsai Launches Telemetry Platform to Connect All Farm Equipment — Autonomous or Not

Bonsai Robotics

Bonsai Robotics Inc. ("Bonsai"), a leading developer of agriculture AI solutions, announced the launch of its proprietary offering for building a transformative connected farming platform for high-value crops. The company’s software ecosystem, Teletrace ™, will expand from support of its fully autonomous machines to enabling conventional tractors and implements to be monitored and managed through the same digital interface. This new intelligent management solution is powered by the Topcon CL-55, a compact telemetry device that plugs directly into the existing CAN bus — a standard interface on most modern tractors and implements. With this connection, real-time machine data is transmitted via Topcon’s CloudLink service and seamlessly integrated into Bonsai’s cloud platform. Growers can monitor and manage every piece of equipment — new or old, autonomous or not — through a single, unified interface powered by Bonsai’s Teletrace ecosystem. “Bonsai’s mission is to bring the AI revolution to the field by unlocking the ability to reimagine how machines are built, deployed, and managed,” said Tyler Niday, CEO and co-founder of Bonsai. “Our solution is no longer limited to just autonomous equipment. Now, any farm machinery, regardless of make or vintage, can be transformed into a smart machine utilizing Teletrace allowing growers to manage mixed fleets from anywhere and track operational utilization, performance and metrics such as harvest rate, input usage and more.” Bonsai’s autonomy system is purpose-built for the harsh, variable conditions of orchard environments – where GPS, LiDAR, and satellite-based systems often fall short, and dust is a constant challenge. In addition, the company’s vision-based autonomy stack enables reliable operation under dense canopy, uneven terrain and without GPS dependency. With Teletrace, growers can now reduce operator error through digital job dispatching and smart implement control and prepare for phased autonomy adoption without the cost of full equipment upgrades. “Permanent crops have seen mechanical innovation, but not digital transformation,” Niday added. “We are here to change that. With Bonsai, the orchard is no longer an offline black hole of information, but now a connected, intelligent system.” This launch follows successful deployments across almonds, pistachios and citrus operations in California and Australia, where growers are using Bonsai to automate spraying, mowing, disking, shaking and sweeping— and now, to track and manage conventional equipment as well. The company’s long-term vision is to manage a diverse set of machines across brands, horsepower ranges, and autonomy levels from a single, intuitive platform. About Bonsai Robotics Bonsai Robotics Inc. is reimagining farming production systems with an AI-first approach to provide vision-based autonomous solutions for harsh environments. Based on patented AI models, a leading orchard data set and computer-vision software, Bonsai’s solutions integrate seamlessly to make OEM equipment operate autonomously. Bonsai technology can navigate in GNSS-denied environments, without a cellular or internet connection, making the highly affordable technology ideal for the toughest physical conditions where dust, darkness, debris, elevation changes and vibration may occur. Learn more at https://www.bonsairobotics.ai/ Contact Details Bonsai Media Contact: Erika Poppelreiter erika@soldiercreekcommunications.com

June 26, 2025 08:15 AM Pacific Daylight Time

Image

NeuroSense Inches Closer to Pharma Partnership as Canadian Regulatory Progress Turns Heads

The Finance Herald

NeuroSense Therapeutics (NASDAQ: NRSN)* has completed a key pre-submission meeting with Health Canada for its ALS drug PrimeC, signaling potential upcoming eligibility for Canada’s fast-track approval pathway (NOC/c). The positive tone reported from the meeting could signal accelerated Canadian approval coming soon and could also potentially advance negotiations for the partnership with a global pharma player. With strong Phase 2b data and a potential $100–150M of peak revenue from Canadian market alone, this milestone could be a catalyst for regulatory momentum and investor revaluation. ‎ NeuroSense Therapeutics (NASDAQ: NRSN) may be nearing a turning point in its ALS drug development journey, and the market is starting to take notice. The Israeli biotech just disclosed that it held a pivotal pre-submission meeting with Health Canada for PrimeC, its lead ALS candidate, potentially setting the stage for both early approval and the finalization of a major pharma partnership. In a Form 6-K filed with the SEC, NeuroSense confirmed the completion of a pre-New Drug Submission (pre-NDS) meeting with regulators to explore eligibility for Canada’s fast-track approval mechanism, known as the Notice of Compliance with Conditions (NOC/c). The company described the discussion as “constructive” and left the meeting “highly encouraged”, language that signals regulatory alignment and opens the door for PrimeC to potentially Canadian patients much sooner than expected. For ALS patients in Canada—and a company with a current ~$52 million valuationm that kind of timeline could prove transformational. But the Health Canada development is more than just a regulatory checkpoint—it’s a potential trigger for something bigger. Back in December 2024, NeuroSense signed a binding term sheet with a global pharmaceutical company, covering full Phase 3 funding, upfront cash, milestone payments, and double-digit royalties. A positive signal from Canadian authorities could be the validation needed to cement that deal and set the stage for global expansion. PrimeC already has data to back up its ambitions. In its Phase 2b PARADIGM trial, the therapy showed a 36% slowdown in ALS progression and a 43% improvement in survival compelling outcomes in a field where treatment options are few and efficacy gains are hard-won. That performance is part of what’s drawing interest from the industry—and why a Canadian approval could serve as a powerful launchpad, both commercially and strategically. The Canadian ALS market alone could support $100–150 million in annual peak sales, according to company estimates. But what’s arguably more valuable is the opportunity to generate real-world data and establish market traction ahead of broader approvals, particularly in the U.S. and Europe. Investors likely won’t have to wait long for clarity. NeuroSense expects to receive official meeting minutes from Health Canada shortly and will update the market once eligibility is confirmed. If successful, the NDS filing and Phase 3 launch would likely follow. In a sector defined by long timelines and uncertain outcomes, NeuroSense now finds itself in a rare position, with validated clinical data, regulatory momentum, and a pending global partnership that could reprice the story entirely. The next few months may determine whether PrimeC becomes not only a commercial product, but also a cornerstone of a much larger biotech success. ‎ Read more from the Finance Herald The New Digital Iron Curtain: How the EU’s Digital Services Act Threatens American Free Speech The Nobel Dilemma: Should Trump Embrace or Reject a Controversial Legacy? New York City’s Political Revolution: Zohran Mamdani’s Far-Left Vision Sparks National Debate States Challenge Trump Administration’s Funding Cuts in Major Legal Battle Heating Up: Power Crisis Strikes the Eastern U.S. Amid Record Temperatures ‎ ‎ * ⚠︎ Paid Advertisement: This content is a paid advertisement. Wall Street Wire has received compensation from NeuroSense Therapeutics Ltd. for promotional media services provided on an ongoing subscription basis. This content is for informational purposes only and does not constitute financial advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details and information regarding the operator of Wall Street Wire are available redditwire.com/terms. We are not responsible for any price targets that may be cited in this article nor do we endorse them, they are quoted based on publicly available news reports and additional price targets may exist that may not have been quoted. Readers are advised to refer to the full reports mentioned on various systems and the disclaimers/disclosures they may be subject to. Contact Details ‎ media.globalmarkets@gmail.com

June 26, 2025 09:24 AM Eastern Daylight Time

Image

This $13M Biotech Has $40M in Pentagon Funding – Here’s Why BiomX Could Be Biotech’s Best-Kept Secret

VentureBlock

With 3X Its Market Cap in Military Grants and Analyst Targets of $15-16, This Military-Backed Phage Therapy Pioneer Trades at Just $0.48 (NYSE: PHGE)*, all while their competitor (NYSE: ARMP) trades at over 6X ‎‎ BiomX Inc. (NYSE: PHGE)* presents an unusual situation in biotech: a company trading at just below a $13 million market cap that has secured $40 million in non-dilutive funding from the U.S. Defense Health Agency. This Pentagon backing, administered through the Naval Medical Research Command, has enabled the company to advance its bacteriophage therapies without the typical shareholder dilution that plagues early-stage biotechs. The military’s interest centers on antibiotic-resistant infections emerging from conflict zones. According to BiomX CEO Jonathan Solomon, medical personnel are “seeing soldiers coming out of the Ukraine war with extremely antibiotic-resistant infections.” This real-world crisis has elevated phage therapy, using viruses that naturally kill bacteria, from scientific curiosity to strategic priority. ‎ The Numbers Behind the Story BiomX’s recent Phase 2 DANCE trial results help explain the military’s confidence. The study of 41 patients with diabetic foot osteomyelitis showed: Statistically significant reduction in ulcer size by week 12 (p=0.046) Greater than 40% difference in healing between treatment and placebo groups by week 10 Significant improvement in ulcer depth at week 13 (p=0.048) Significant reduction in ulcer area expansion (p=0.017) No serious adverse events These results matter because diabetic foot infections lead to approximately 160,000 amputations annually in the U.S., creating an $8 billion healthcare burden. The same Staphylococcus aureus bacteria causing these civilian amputations also complicates combat wound care, making BX211 a dual-use technology. ‎ Beyond Military Applications While defense funding validates the technology, BiomX’s commercial opportunity spans multiple indications. The company’s BX004 program for cystic fibrosis demonstrated that 14.3% of patients (3 out of 21) completely cleared chronic Pseudomonas aeruginosa lung infections after 10 days of treatment, compared to 0% in the placebo group. One patient had carried the infection for 35 years before achieving clearance. BiomX estimates addressable markets of $2.5 billion globally for diabetic foot infections and $1.6 billion for cystic fibrosis. The FDA has already granted Fast Track and Orphan Drug designations to BX004, potentially accelerating the regulatory pathway. ‎ The Market Disconnect & Opportunity Current analyst coverage reveals a striking valuation gap. H.C. Wainwright maintains a Buy rating with a $15 price target, while Laidlaw & Company also rates the stock Buy with a $16 target. From recent trading levels around $0.52, these targets represent potential upside of approximately 2,800-2,900%. Laidlaw analyst Yale Jen called the BX211 Phase 2 results “an absolutely positive surprise,” characterizing the asset as “high value and clinically de-risked.” H.C. Wainwright’s assessment emphasizes the program’s advancement toward “important regulatory discussions” with the FDA. The disconnect becomes even more apparent when compared to peers. Armata Pharmaceuticals (NYSE: ARMP), the only other publicly-traded pure-play phage therapy company, trades at approximately $70 million, more than 5X BiomX’s valuation despite having just one clinical program compared to BiomX’s two Phase 2 assets and $40 million in military backing. ‎ Understanding the Opportunity Several factors contribute to BiomX's current valuation disconnect: Non-dilutive funding advantage: The $40 million military grant has funded clinical development without issuing new shares, preserving value for existing shareholders. Limited competition: No new drugs have been approved specifically for diabetic foot osteomyelitis in over 20 years, giving BiomX potential first-mover advantage in a massive unmet need. Impressive platform validation: Success in two separate indications (DFO and cystic fibrosis) demonstrates the broader applicability of the phage platform. Near-term catalysts: Phase 2b results for BX004 expected in Q1 2026, FDA meetings for BX211 Phase 2/3 design, and potential additional military funding or partnerships. ‎ The Broader Context BiomX operates within converging megatrends. The Biden administration has proposed $88.2 billion for biodefense over five years, while organizations like DARPA and ARPA-H are investing hundreds of millions in next-generation antimicrobials. NATO has formed a task force specifically to reintroduce phage therapy in military medicine. The company’s ability to address both military and civilian needs positions it uniquely as governments worldwide recognize antimicrobial resistance as a national security threat. With China producing 80-90% of antibiotic raw materials, supply chain vulnerabilities add urgency to developing alternative therapies. ‎ Looking Ahead BiomX’s story combines validated science, government backing, and massive market opportunities with a market cap that appears disconnected from fundamental value. The $40 million in Pentagon funding alone exceeds the company’s current market valuation by 3X, while clinical success and analyst targets suggest significant upside potential. As the company advances toward Phase 2/3 trials for BX211 and awaits Phase 2b results for BX004, the convergence of military necessity and civilian healthcare needs could transform this overlooked biotech into a key player in humanity’s fight against antibiotic-resistant infections. ‎ This article was syndicated from VentureBlock. ‎ ‎ Recent News Highlights BiomX: BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025 BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO) ‎ ‎ * ⚠︎ Paid Advertisement Disclaimer: This content is a paid advertisement. Wall Street Wire has received compensation from BiomX Inc. for promotional media services provided on an ongoing subscription basis. This content is for informational purposes only and does not constitute financial advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details and information regarding the operator of Wall Street Wire are available redditwire.com/terms. We are not responsible for any price targets that may be cited in this article nor do we endorse them, they are quoted based on publicly available news reports and additional price targets may exist that may not have been quoted. Readers are advised to refer to the full reports mentioned on various systems and the disclaimers/disclosures they may be subject to. Contact Details ‎ media.globalmarkets@gmail.com

June 26, 2025 08:31 AM Eastern Daylight Time

Image

Vertical IQ and Ignite Sales Partner to Streamline Industry Intelligence Integration for Financial Institutions

Vertical IQ

Industry Intelligence leader Vertical IQ and award-winning bank sales engagement platform Ignite Sales, Inc., recently formed a partnership that enables Vertical IQ content to be dynamically applied within the Ignite Sales Engagement Platform to simplify the user experience for business banking sales and financial institutions. Companies formed with shared objectives This alliance is a natural fit for the two organizations, both of which focus on financial institutions’ sales enablement and success. Originally created by bankers for bankers, Vertical IQ was developed with the goal of delivering actionable, convenient, and focused economic and industry insights to help financial professionals win, grow, and retain more business. The easy-to-use platform has since expanded to serve a broad array of professionals including those within accounting, business process organizations, financial advisory services, insurance, business consultants, and more. Vertical IQ’s content currently covers more than 97% of the economic revenue in the U.S. and Canada through more than 920 Industry Profiles and 3,400 local economic reports. Ignite Sales equips banks with intelligent sales engagement solutions to guide their customers to the right financial products. The Ignite Sales data-driven AI platform delivers interactive, personalized conversations between a banker and a small business customer, helping them uncover the customer’s unique banking needs. The platform also allows self-service users on a financial institution’s website to explore personalized financial solutions that fit each business’s unique needs. One-stop access to valuable industry content The collaboration between Vertical IQ and Ignite Sales integrates Vertical IQ’s robust industry and economic content directly into the Ignite Sales platform, enabling frontline bankers to access useful Industry Intelligence in real-time during customer conversations. The integration not only enhances the value of each customer interaction, but also simplifies the user experience for the two companies’ shared financial institution clients. “Our partnership with Ignite Sales is about empowering bankers with actionable insights exactly when and where they need them,” said Paul Hock, VP of Sales and Strategic Partnerships at Vertical IQ. “By surfacing elements of our Industry Intelligence directly within the Ignite platform — and simplifying access to additional Vertical IQ content — we’re enabling more informed conversations that lead to deeper relationships and better outcomes for the bank or credit union and their customer.” The alliance between the two organizations also addresses a growing demand among banks to streamline the processes used by their frontline teams, saving time while still delivering personalized, consultative experiences for customers. By embedding Vertical IQ content directly into the Ignite platform, bankers can now access key industry trends, pain points, and financial benchmarks without switching between platforms, making it easier to guide customers and prospects through their financial journeys. The result is more knowledgeable and confident bankers and higher satisfaction of businesses with their business banking experience. “Our mission at Ignite Sales has always been to help financial institutions deliver exceptional, tailored customer experiences that enhance banker confidence and business satisfaction during the sales process,” said Ken Patrick, Chief Growth Officer of Ignite Sales. “This partnership with Vertical IQ takes that commitment to the next level by providing bankers with immediate access to high-value industry data within our digital engagement service. The result is smarter conversations and a seamless experience for our financial services clients.” The integration is currently being rolled out with the two companies’ joint financial institution clients and is expected to be available to all Ignite Sales users in Q4 of 2025. To learn more about Vertical IQ or to request a demo, visit www.verticaliq.com. For more information about Ignite Sales or to schedule a demo, go to www.ignitesales.com. ABOUT VERTICAL IQ Headquartered in Raleigh, N.C., Vertical IQ is a nationally recognized leader in Industry Intelligence. Whether they’re pitching a local brewery or a national biotech company, successful sales, marketing and customer success teams use Vertical IQ to better understand a prospect’s or client’s business challenges before, during and after meetings. Covering more than 97% of the economic revenue in the U.S. and Canada through more than 920 Industry Profiles and 3,400 local economic reports, Vertical IQ equips users with the confidence and credibility to make memorable first impressions and sustain enduring relationships. ABOUT IGNITE SALES Ignite Sales’ patented data-driven AI sales engagement platform digitally empowers bankers and self-service users for significant performance impact. Using artificial intelligence and behavioral science proven for over 20 years with the industry’s leading financial institutions, Ignite’s award-winning analytics enlightens bank management with valuable information unattainable with any other fintech platform. Ignite is the only provider in the market that helps financial institutions, bankers and users discover and uncover relevant personal needs at the center of every customer journey. As a result, financial institutions increase customer satisfaction while unifying all channels to provide a consistent experience, as well as increase sales by digitally guiding and empowering customers to make confident, comprehensive and accurate buying decisions. Visit us at www.ignitesales.com, on LinkedIn and X @IgniteSales. Contact Details Julie Gilbert +1 919-787-4600 jgilbert@verticaliq.com Company Website https://verticaliq.com/

June 26, 2025 08:00 AM Eastern Daylight Time

First Global Smart Machinery and Electronics Expo hosted by China Electronics Chamber of Commerce will be held in December

Grand Newswire

The inaugural Global Artificial Intelligence Machines and Electronics Expo will take place in Macao and Zhuhai from December 4, 2025, adopting an innovative "One Expo, Two Cities" model.This Expo is hosted by China Electronics Chamber of Commerce. The three-day event will open to professional visitors for the first two days and to the public on the third day, expecting over 70,000 professional attendees. A press conference held by the Guangdong Provincial Government on June 23.Themed "Bay Area Intelligence, Globally Embraced," it positions itself as a "Technology Trendsetter, Global Networking Hub, and Industry Accelerator" to enhance the GBA’s influence in global smart manufacturing. Amid intensifying global tech competition, breakthroughs in artificial intelligence, quantum computing, and low-altitude economy are reshaping industries, with smart machinery and electronics as core battlegrounds. The Expo will showcase leading enterprises and high-growth startups, with representatives from the United Nations International Trade Centre and the International Semiconductor Industry Association attending. This Expo adopts the "One Expo, Two Cities" model, featuring a "1+1+6+N" framework: one opening ceremony, one keynote forum, six themed pavilions, and numerous sub-forums, new technology launches, and supply-demand matchmaking sessions. Macao’s venue will focus on smart electronics, spanning 40,000 square meters with 500 exhibitors across three pavilions: Smart Communications and IoT, Smart Audio-Visual and Metaverse, and Venture Capital and International Exhibition. Exhibits in Macao will include satellite communications, integrated circuits, advanced displays, smartphones, AR/VR/XR products, wearable devices, and cutting-edge innovation projects. Zhuhai’s venue will emphasize smart machinery, covering 30,000 square meters with 500 exhibitors in three pavilions: Smart Equipment and Industrial Internet, Intelligent Transportation and Future Mobility, and Smart Home and Health Technology. Zhuhai’s displays will feature robotics, digital transformation solutions, new energy vehicles, intelligent driving, drones, low-altitude technologies, smart homes, and smart healthcare applications. The Expo is guided by Guangdong’s Commerce and Industry Departments, hosted by the China Electronics Chamber of Commerce, and supported by the Hengqin Guangdong-Macao In-Depth Cooperation Zone, Macao’s Trade and Investment Promotion Institute, and Zhuhai’s government. The Expo fosters capital-technology synergy and shared manufacturing resources, creating an integrated industrial ecosystem for exhibitors. Roadshows will commence in Beijing, followed by international events in Germany, Thailand, and Indonesia, and domestic promotions in Shanghai, Hangzhou, Chengdu, and Shenzhen. Media promotion will combine authoritative mainstream outlets with vertical industry media for credible outreach and precise targeting of global decision-makers. This Expo will fully leverage new media platforms like Douyin, Kuaishou, Xiaohongshu, and YouTube to build an interactive ecosystem, amplifying the Expo’s global reach and influence. About China Electronics Chamber of Commerce The China Electronics Chamber of Commerce (CECC), founded in 1988, is a national and industrial social organization formed voluntarily by enterprises, institutions, social groups, industry experts and scholars engaged in the electronic information industry including product production, operation, scientific research, teaching, services, internet and Al in China. The CECC is registered with the Ministry of Civil Affairs and has the status of an independent legal entity. Its party building and personnel is under the management of the Society Work Department of the CPC Central Committee, the major industry management authority is the Ministry of Industry and Information Technology (MIIT), and its highest authority is the General Assembly of Members & General Council. Through its 8 systems, 9 platforms, 10 departments and 38 professional committees (including committees under preparation), the CECC provides high-quality member services and business support to more than 16,500 direct members, branch members, professional members and group members. Contact Details China Electronics Chamber of Commerce Li xu service@cecc.org.cn Company Website https://www.cecc.org.cn/english/

June 26, 2025 02:47 AM Eastern Daylight Time

Image

The Reservoir and Naturipe Berry Growers Partner to Accelerate Strawberry Farming and Innovation in Salinas Valley

The Reservoir

The Reservoir, a California nonprofit building a new system for agricultural innovation, has partnered with Naturipe Berry Growers, Inc., one of North America’s oldest and most respected strawberry growers, to bring dedicated farming innovation and commercialization to Reservoir Farms, its flagship on-farm startup incubator in Salinas Valley. As the second farming partner following Tanimura & Antle, Naturipe brings deep berry-growing expertise, reinforcing Reservoir Farm’s commitment to advancing high-quality specialty crops. The partnership lays the foundation for a long-term innovation, bridging cutting-edge research with real-world farming systems. Located at the intersection of Highway 68 and Hitchcock Road, the Reservoir Farms site is minutes from downtown Salinas and sits in the heart of one of the most productive specialty crop regions in the world. With 15 acres under development, Reservoir Farms is purpose-built to provide startups with direct access to farmland, infrastructure, and growers—offering the kind of in-field testing and feedback loop that’s essential for bringing new technologies to market. Under the terms of the partnership, Naturipe will manage an initial five acres of strawberries at Reservoir Farms, overseeing all aspects of planting, field preparation, harvesting, and production. The company will also work closely with The Reservoir and participating startups to explore opportunities for technology integration, field validation, and innovation in sustainable farming. “Naturipe brings unmatched farming leadership, a deep-rooted commitment to the Salinas Valley, and a strong belief in what’s next for agriculture,” said Danny Bernstein, founder and CEO of The Reservoir. “This partnership represents the best of what Reservoir Farms is about—bringing experienced growers together with innovators to build practical, scalable solutions that serve the entire agricultural community.” The collaboration represents hundreds of thousands of dollars in annual in-kind value, contributed by Naturipe in the form of operational support, infrastructure, and agronomic expertise. In recognition of its leadership, Naturipe will be named a Premier Sponsor of Reservoir Farms and will play a central role in shaping both operations and strategic programming on-site. “We see Reservoir Farms as a unique platform to accelerate innovation that’s grounded in real farming,” said Hank Guerrero, Vice President of Ag Operations at Naturipe Berry Growers. “Our partnership is a natural extension of our values—supporting a stronger, smarter, and more sustainable future for specialty crop agriculture.” A New Model for AgTech Deployment Founded in 2024, the Reservoir is building a new ecosystem for agricultural innovation—connecting startups, growers, and institutions to solve generational challenges in farming. Reservoir Farms is its flagship program: a nonprofit, on-farm startup incubator that helps agricultural robotics, automation, and digital solutions scale faster by embedding them in working production environments. Reservoir Farms Salinas is the first of multiple locations set to launch across California, with the goal of bridging the gap between prototype and adoption by breaking down the barriers separating Silicon Valley innovation from farmland. With support from partners like Naturipe, startups will be able to iterate rapidly, generate critical performance data, and build trust with the growers who rely on their tools. Reservoir Farms will dedicate portions of its acreage to key crops in Salinas Valley—starting with strawberries, leafy greens, and vegetables—using staggered planting schedules and variable plot sizes to support a wide range of pilot activity. The site will also feature co-working facilities, infrastructure for equipment testing, and shared services to support early-stage ventures. Built to Scale Impact Across Agriculture Reservoir Farms is committed to: Empowering Farmers: Providing access to the latest technologies to help address labor shortages, improve yields, and reduce input costs. Accelerating Startups: Supporting over 50 early-stage companies within the first five years through direct field engagement. Boosting the Local Economy: Creating over 500 high-quality jobs and new career pathways in high-tech agriculture. Driving Sustainability: Piloting technologies that support water efficiency, improved soil health, and regenerative farming practices. “This initiative reinforces the Salinas Valley’s role as a global leader in agricultural innovation,” Bernstein said. “Together with Naturipe, we’re building a launchpad that turns visionary ideas into practical, profitable, and climate-resilient solutions for California and beyond.” The official groundbreaking for Reservoir Farms is planned for late summer 2025. # # # About the Reservoir: The Reservoir is a new system for specialty crop innovation. Reservoir Farms is a nonprofit, on-farm startup incubator that helps agricultural robotics and automation companies develop, test, and scale breakthrough technologies directly in working farm environments. It’s designed to close the gap between promising prototypes and real-world deployment—accelerating solutions to urgent challenges in agriculture while supporting inclusive rural economic development. Reservoir Ventures, the Reservoir’s affiliated venture fund, invests in the most promising startups emerging from the incubator. Learn more at www.reservoir.co. About Naturipe Berry Growers: Founded in 1917, Naturipe Berry Growers, Inc. is one of the oldest and largest strawberry grower-shippers in North America. With deep roots in the Salinas Valley, Naturipe is committed to sustainable farming, community leadership, and forward-thinking partnerships that position growers for long-term success. The company supports cutting-edge research, responsible land stewardship, and innovative collaborations that advance the future of agriculture. Contact Details AgTech PR for The Reservoir Jennifer Goldston jennifer@agtechpr.com Company Website https://www.thersvr.org/

June 25, 2025 09:00 AM Pacific Daylight Time

Image

Cisco & Qualcomm Extend Direxion’s Edge in Single Stock Daily Leveraged & Inverse ETFs

Direxion

Direxion, a leading provider of ETFs for tactical traders, and a pioneer in Single Stock Daily Leveraged & Inverse ETFs, expanded its industry-leading lineup of high-powered trading tools with the launch of four new funds tracking the performance of Cisco Systems, Inc. (CSCO) and QUALCOMM Incorporated (QCOM). These funds provide traders with amplified, or inverse, exposure to CSCO or QCOM via the Direxion Daily CSCO Bull 2X ETF ( Ticker: CSCL ) and Direxion Daily CSCO Bear 1X ETF ( Ticker: CSCS ), or the Direxion Daily QCOM Bull 2X ETF ( Ticker: QCMU ) and Direxion Daily QCOM Bear 1X ETF ( Ticker: QCMD ). “Cisco and Qualcomm are at the forefront of networking and wireless innovation, sectors that are integral to the digital economy,” said Douglas Yones, CEO of Direxion. “By introducing these ETFs, we empower traders to capitalize on short-term movements in these pivotal technology stocks, reflecting our commitment to providing targeted tools for dynamic market engagement." Designed for active traders, Direxion’s pairs of Single Stock Leveraged & Inverse ETFs are built for short-term trading – not long-term investing. These ground-breaking trading tools are intended for experienced traders with a high risk tolerance. Unlike traditional ETFs, or even other leveraged and/or inverse ETFs, these products track the price of a single stock rather than an index, offering no diversification benefits. All Direxion Leveraged and Inverse ETFs are intended only for investors with an in-depth understanding of the risks associated with seeking leveraged investment results, and who plan to actively monitor and manage their positions. There is no guarantee these ETFs will meet their objective. Please visit the Direxion Leveraged and Inverse ETF Education Center, where you will find educational brochures, videos, and a self-paced online course to help you understand if Leveraged and Inverse ETFs – including Single Stock Daily LETFs – are right for you. About Direxion: Direxion equips investors who are driven by conviction with ETF solutions built for purpose and fine-tuned for precision. These solutions are available for a broad spectrum of investors, whether executing short-term tactical trades, or investing in thematic strategies. Direxion’s reputation is founded on developing products that precisely express market perspectives and allow investors to manage their risk exposure. Founded in 1997, the company has approximately $40.7 billion in assets under management as of March 31, 2025. For more information, please visit www.direxion.com. There is no guarantee that the Funds will achieve their investment objectives. For more information on all Direxion Shares ETFs, go to www.direxion.com, or call us at 866.301.9214. An investor should carefully consider a Fund’s investment objective, risks, charges, and expenses before investing. A Fund’s prospectus and summary prospectus contain this and other information about the Direxion Shares. To obtain a prospectus and summary prospectus call 866.476.7523 or visit our website at direxion.com. A Fund’s prospectus and summary prospectus should be read carefully before investing. Investing in the funds involves a high degree of risk. Unlike traditional ETFs, or even other leveraged and/or inverse ETFs, these leveraged and/or inverse single-stock ETFs track the price of a single stock rather than an index, eliminating the benefits of diversification. Leveraged and inverse ETFs pursue daily leveraged investment objectives, which means they are riskier than alternatives which do not use leverage. They seek daily goals and should not be expected to track the underlying stock’s performance over periods longer than one day. They are not suitable for all investors and should be utilized only by investors who understand leverage risk and who actively manage their investments. The Funds will lose money if the underlying stock’s performance is flat, and it is possible that the Bull Fund will lose money even if the underlying stock’s performance increases, and the Bear Fund will lose money even if the underlying stock’s performance decreases, over a period longer than a single day. Investing in the Funds is not equivalent to investing directly in CSCO or QCOM. Direxion Shares Risks – An investment in a Fund involves risk, including the possible loss of principal. Each Fund is non-diversified and includes risks associated with a Fund concentrating its investments in a particular security, industry, sector, or geographic region which can result in increased volatility. A Fund's investments in derivatives such as futures contracts and swaps may pose risks in addition to, and greater than, those associated with directly investing in securities or other investments, including imperfect correlations with underlying investments or the Fund's other portfolio holdings, higher price volatility and lack of availability. As a result, the value of an investment in a Fund may change quickly and without warning. Leverage Risk – The Bull Fund obtains investment exposure in excess of its net assets by utilizing leverage and may lose more money in market conditions that are adverse to its investment objective than a fund that does not utilize leverage. A total loss may occur in a single day. Leverage will also have the effect of magnifying any differences in the Fund’s correlation with CSCO or QCOM and may increase the volatility of the Bull Fund. Daily Correlation Risk - A number of factors may affect the Bull Fund’s ability to achieve a high degree of correlation with CSCO or QCOM and therefore achieve its daily leveraged investment objective. The Bull Fund’s exposure to CSCO or QCOM is impacted by CSCO or QCOM’s movement. Because of this, it is unlikely that the Bull Fund will be perfectly exposed to CSCO or QCOM at the end of each day. The possibility of the Bull Fund being materially over- or under-exposed to CSCO or QCOM increases on days when CSCO or QCOM is volatile near the close of the trading day. Daily Inverse Correlation Risk - A number of factors may affect the Bear Fund’s ability to achieve a high degree of inverse correlation with CSCO or QCOM and therefore achieve its daily inverse investment objective. The Bear Fund’s exposure to CSCO or QCOM is impacted by CSCO or QCOM’s movement. Because of this, it is unlikely that the Bear Fund will be perfectly exposed to CSCO or QCOM at the end of each day. The possibility of the Bear Fund being materially over- or under-exposed to CSCO or QCOM increases on days when CSCO or QCOM is volatile near the close of the trading day. Cisco Systems, Inc. Investing Risk – Issuer-specific attributes may cause an investment held by the Fund to be more volatile than the market generally. Cisco Systems, Inc. faces risks associated with: impacts on operations from various avenues; supply chain disruptions; volatility of sales to service providers and cloud markets; changes in distribution; high competition; need to manage strategic alliances; complexities of inventory management; changes in supply and demand for software subscriptions; reliance on new product development; among other risks. QUALCOMM Incorporated Investing Risk – Issuer-specific attributes may cause an investment held by the Fund to be more volatile than the market generally. The value of an individual security or particular type of security may be more volatile than the market as a whole and may perform differently from the value of the market as a whole. QCOM faces risks associated with: concentration of revenues amongst a small number of customers; vertical integration; concentration of business in China; requirements to grow the business and add new products and services; inability to profit from acquisitions and strategic transactions; limitations in supply chain and in demand for products and services; among other risks. Information Technology Sector Risk – The value of stocks of information technology companies, and companies that rely heavily on technology, is particularly vulnerable to rapid changes in technology product cycles, rapid product obsolescence, government regulation, and competition, both domestically and internationally, including competition from competitors with lower production costs. Semiconductor Industry Risk – Semiconductor companies may face intense competition, both domestically and internationally, and such competition may have an adverse effect on such companies’ profit margins. Semiconductor companies may have limited product lines, markets, financial resources or personnel. Companies in the semiconductor industry may have products that face obsolescence due to rapid technological developments and frequent new product introduction, unpredictable changes in growth rates and competition for qualified personnel. Additional risks of each Fund include Effects of Compounding and Market Volatility Risk, Derivatives Risk, Counterparty Risk, Rebalancing Risk, Intra-Day Investment Risk, Industry Concentration Risk, Market Risk, Indirect Investment Risk, and Cash Transaction Risk. Additionally, for the Direxion Daily CSCO Bear 1X ETF and Direxion Daily QCOM Bear 1X ETF, Shorting or Inverse Risk. Please see the summary and full prospectuses for a more complete description of these and other risks of a Fund. Distributor: ALPS Distributors, Inc. Contact Details Ditto Public Relations Danielle Black, AD direxion@dittopr.co Company Website https://www.direxion.com/

June 25, 2025 09:00 AM Eastern Daylight Time

1 2 3 4 5 ... 705